INTEGRA LIFESCIENCES HOLDING (IART) Stock Fundamental Analysis

NASDAQ:IART • US4579852082

11.38 USD
+0.05 (+0.44%)
At close: Feb 27, 2026
11.38 USD
0 (0%)
After Hours: 2/27/2026, 8:09:25 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

IART gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of IART have multiple concerns. IART is cheap, but on the other hand it scores bad on growth.


Dividend Valuation Growth Profitability Health

3

1. Profitability

1.1 Basic Checks

  • IART had positive earnings in the past year.
  • IART had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: IART reported negative net income in multiple years.
  • IART had a positive operating cash flow in 4 of the past 5 years.
IART Yearly Net Income VS EBIT VS OCF VS FCFIART Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

1.2 Ratios

  • IART has a Return On Assets (-13.58%) which is comparable to the rest of the industry.
  • IART has a Return On Equity (-47.74%) which is comparable to the rest of the industry.
  • IART's Return On Invested Capital of 4.27% is fine compared to the rest of the industry. IART outperforms 74.05% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for IART is below the industry average of 8.75%.
Industry RankSector Rank
ROA -13.58%
ROE -47.74%
ROIC 4.27%
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
IART Yearly ROA, ROE, ROICIART Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2 4 6 8 10

1.3 Margins

  • IART has a Operating Margin of 10.22%. This is in the better half of the industry: IART outperforms 78.92% of its industry peers.
  • In the last couple of years the Operating Margin of IART has declined.
  • The Gross Margin of IART (57.21%) is comparable to the rest of the industry.
  • IART's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 10.22%
PM (TTM) N/A
GM 57.21%
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
IART Yearly Profit, Operating, Gross MarginsIART Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), IART is destroying value.
  • There is no outstanding debt for IART. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IART Yearly Shares OutstandingIART Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IART Yearly Total Debt VS Total AssetsIART Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

  • Based on the Altman-Z score of 1.23, we must say that IART is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of IART (1.23) is comparable to the rest of the industry.
  • IART has a Debt/Equity ratio of 1.73. This is a high value indicating a heavy dependency on external financing.
  • The Debt to Equity ratio of IART (1.73) is worse than 80.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.73
Debt/FCF N/A
Altman-Z 1.23
ROIC/WACC0.57
WACC7.56%
IART Yearly LT Debt VS Equity VS FCFIART Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.3 Liquidity

  • IART has a Current Ratio of 3.14. This indicates that IART is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of IART (3.14) is comparable to the rest of the industry.
  • IART has a Quick Ratio of 1.80. This is a normal value and indicates that IART is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.80, IART is in line with its industry, outperforming 48.11% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.14
Quick Ratio 1.8
IART Yearly Current Assets VS Current LiabilitesIART Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • IART shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.89%.
  • The Earnings Per Share has been decreasing by -1.86% on average over the past years.
EPS 1Y (TTM)-12.89%
EPS 3Y-12.69%
EPS 5Y-1.86%
EPS Q2Q%-14.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-1.74%

3.2 Future

  • IART is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.47% yearly.
  • Based on estimates for the next years, IART will show a small growth in Revenue. The Revenue will grow by 2.83% on average per year.
EPS Next Y7.53%
EPS Next 2Y9.61%
EPS Next 3Y8.47%
EPS Next 5YN/A
Revenue Next Year2.71%
Revenue Next 2Y3.14%
Revenue Next 3Y2.83%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IART Yearly Revenue VS EstimatesIART Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 500M 1B 1.5B
IART Yearly EPS VS EstimatesIART Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

7

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 5.10, the valuation of IART can be described as very cheap.
  • 98.92% of the companies in the same industry are more expensive than IART, based on the Price/Earnings ratio.
  • IART is valuated cheaply when we compare the Price/Earnings ratio to 27.10, which is the current average of the S&P500 Index.
  • IART is valuated cheaply with a Price/Forward Earnings ratio of 4.75.
  • IART's Price/Forward Earnings ratio is rather cheap when compared to the industry. IART is cheaper than 99.46% of the companies in the same industry.
  • IART is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.06, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 5.1
Fwd PE 4.75
IART Price Earnings VS Forward Price EarningsIART Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • IART's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. IART is cheaper than 95.68% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 7.56
IART Per share dataIART EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.68
PEG (5Y)N/A
EPS Next 2Y9.61%
EPS Next 3Y8.47%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for IART!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INTEGRA LIFESCIENCES HOLDING

NASDAQ:IART (2/27/2026, 8:09:25 PM)

After market: 11.38 0 (0%)

11.38

+0.05 (+0.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-26
Earnings (Next)05-04
Inst Owners95.82%
Inst Owner Change1.11%
Ins Owners3.07%
Ins Owner Change0.13%
Market Cap886.39M
Revenue(TTM)N/A
Net Income(TTM)-495.33M
Analysts54.12
Price Target15.81 (38.93%)
Short Float %11.41%
Short Ratio10.4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.96%
Min EPS beat(2)2.22%
Max EPS beat(2)21.7%
EPS beat(4)3
Avg EPS beat(4)7.07%
Min EPS beat(4)-6.76%
Max EPS beat(4)21.7%
EPS beat(8)4
Avg EPS beat(8)3.13%
EPS beat(12)6
Avg EPS beat(12)3.64%
EPS beat(16)8
Avg EPS beat(16)4.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.86%
Min Revenue beat(2)-4.85%
Max Revenue beat(2)3.14%
Revenue beat(4)1
Avg Revenue beat(4)-1.45%
Min Revenue beat(4)-4.85%
Max Revenue beat(4)3.14%
Revenue beat(8)1
Avg Revenue beat(8)-1.23%
Revenue beat(12)2
Avg Revenue beat(12)-1.2%
Revenue beat(16)3
Avg Revenue beat(16)-0.96%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.23%
EPS NY rev (1m)0%
EPS NY rev (3m)0.04%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.24%
Valuation
Industry RankSector Rank
PE 5.1
Fwd PE 4.75
P/S 0.54
P/FCF N/A
P/OCF 9.93
P/B 0.85
P/tB N/A
EV/EBITDA 7.56
EPS(TTM)2.23
EY19.6%
EPS(NY)2.4
Fwd EY21.07%
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)1.15
OCFY10.08%
SpS21.09
BVpS13.32
TBVpS-9.47
PEG (NY)0.68
PEG (5Y)N/A
Graham Number25.85
Profitability
Industry RankSector Rank
ROA -13.58%
ROE -47.74%
ROCE 5.11%
ROIC 4.27%
ROICexc 4.65%
ROICexgc 11.32%
OM 10.22%
PM (TTM) N/A
GM 57.21%
FCFM N/A
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
ROICexc(3y)6.8%
ROICexc(5y)7%
ROICexgc(3y)25.35%
ROICexgc(5y)25.69%
ROCE(3y)7.3%
ROCE(5y)7.36%
ROICexgc growth 3Y-1.99%
ROICexgc growth 5Y0.59%
ROICexc growth 3Y-12.19%
ROICexc growth 5Y-7.26%
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
F-Score5
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 1.73
Debt/FCF N/A
Debt/EBITDA 5.62
Cap/Depr 68.73%
Cap/Sales 6.32%
Interest Coverage 250
Cash Conversion 28.01%
Profit Quality N/A
Current Ratio 3.14
Quick Ratio 1.8
Altman-Z 1.23
F-Score5
WACC7.56%
ROIC/WACC0.57
Cap/Depr(3y)58.38%
Cap/Depr(5y)54.07%
Cap/Sales(3y)4.82%
Cap/Sales(5y)4.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.89%
EPS 3Y-12.69%
EPS 5Y-1.86%
EPS Q2Q%-14.43%
EPS Next Y7.53%
EPS Next 2Y9.61%
EPS Next 3Y8.47%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-1.74%
Revenue Next Year2.71%
Revenue Next 2Y3.14%
Revenue Next 3Y2.83%
Revenue Next 5YN/A
EBIT growth 1Y-9.4%
EBIT growth 3Y-13.07%
EBIT growth 5Y-6.81%
EBIT Next Year17.61%
EBIT Next 3Y9.61%
EBIT Next 5Y8.11%
FCF growth 1Y-113.18%
FCF growth 3Y-61.56%
FCF growth 5Y-31.13%
OCF growth 1Y-46.39%
OCF growth 3Y-25.46%
OCF growth 5Y-10.98%

INTEGRA LIFESCIENCES HOLDING / IART FAQ

Can you provide the ChartMill fundamental rating for INTEGRA LIFESCIENCES HOLDING?

ChartMill assigns a fundamental rating of 3 / 10 to IART.


What is the valuation status for IART stock?

ChartMill assigns a valuation rating of 7 / 10 to INTEGRA LIFESCIENCES HOLDING (IART). This can be considered as Undervalued.


What is the profitability of IART stock?

INTEGRA LIFESCIENCES HOLDING (IART) has a profitability rating of 3 / 10.


What is the financial health of INTEGRA LIFESCIENCES HOLDING (IART) stock?

The financial health rating of INTEGRA LIFESCIENCES HOLDING (IART) is 3 / 10.